KG&L Capital Management LLC Makes New $46,000 Investment in Aileron Therapeutics, Inc. (NASDAQ:ALRN)

KG&L Capital Management LLC bought a new position in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) during the 3rd quarter, HoldingsChannel reports. The fund bought 13,000 shares of the company’s stock, valued at approximately $46,000.

Other hedge funds have also recently bought and sold shares of the company. Texas Capital Bank Wealth Management Services Inc boosted its position in shares of Aileron Therapeutics by 65.9% during the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock worth $174,000 after acquiring an additional 10,398 shares in the last quarter. Warberg Asset Management LLC acquired a new position in Aileron Therapeutics during the second quarter valued at approximately $86,000. Nantahala Capital Management LLC lifted its stake in Aileron Therapeutics by 82.1% during the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock worth $1,286,000 after purchasing an additional 209,367 shares during the last quarter. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at $4,925,000. 90.89% of the stock is owned by institutional investors.

Aileron Therapeutics Price Performance

Aileron Therapeutics stock opened at $4.00 on Tuesday. The stock has a market cap of $86.68 million, a PE ratio of -1.23 and a beta of 2.35. Aileron Therapeutics, Inc. has a 12-month low of $1.19 and a 12-month high of $7.42. The business’s 50-day moving average price is $3.27 and its two-hundred day moving average price is $3.21.

Aileron Therapeutics (NASDAQ:ALRN) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.20). As a group, analysts expect that Aileron Therapeutics, Inc. will post -1.41 earnings per share for the current year.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).